Psoriasis Phototherapy Denied by Insurance? How to Appeal

Phototherapy — using targeted wavelengths of ultraviolet light to treat skin disease — is a proven, evidence-based treatment for psoriasis that has been used for decades. Narrow-band UVB (NB-UVB) in particular is recommended by every major dermatology guideline as a step in psoriasis management. Yet insurance companies regularly deny phototherapy coverage, dispute access to home units, or use phototherapy as a step therapy requirement while simultaneously refusing to pay for it. Here is how to appeal.

Why Insurers Deny Phototherapy

In-office session frequency limits: Most insurers cover in-office phototherapy but impose session limits (typically 30–40 per year) that are insufficient for optimal treatment. Standard NB-UVB protocols require 3 sessions per week for 12–16+ weeks, totaling 48+ sessions for an initial course.

Home phototherapy unit denials: Insurers frequently deny home NB-UVB units as "not medically necessary" despite clear evidence that home phototherapy is equivalent in efficacy to office-based treatment and dramatically reduces patient burden.

Geographic access barriers ignored: If you live far from a dermatology center with a phototherapy booth, your insurer may still deny home therapy and approve only in-office — in practice leaving you without access to treatment.

Step therapy circular problem: Some insurers require documented phototherapy failure before approving a biologic, but then also deny the phototherapy itself — trapping patients in an administrative loop.

In-Office Phototherapy: Session Limit Disputes

When insurers approve phototherapy but cap session numbers below what treatment requires, your appeal should document:

• Published NB-UVB treatment protocols specifying standard session numbers (typically 24–36 sessions minimum for initial response, 48+ for full course)
• Your treatment response at the point where sessions were cut — PASI, BSA, or PGA scoring at each visit
• Your dermatologist's attestation that the approved number of sessions is insufficient to achieve therapeutic response
• AAD-NPF psoriasis guidelines specifying phototherapy as a recommended treatment without arbitrary session caps

Request that the insurer provide the clinical evidence basis for their session limit. Medical necessity must be determined by the patient's individual clinical needs, not an arbitrary utilization cap.

Home NB-UVB Unit: Building the Approval Case

Home phototherapy units are FDA-cleared medical devices and are cost-effective for insurers compared to repeated office visits. The clinical literature consistently shows equivalent outcomes between home and office NB-UVB for psoriasis.

Your home phototherapy appeal should include:

Geographic access documentation: Distance from nearest in-office phototherapy center, number of locations within practical travel distance, and any transportation limitations (disability, work schedule, childcare responsibilities).

Clinical equivalence evidence: Cite studies comparing home vs. office NB-UVB outcomes — the British Journal of Dermatology and Journal of the American Academy of Dermatology have published multiple equivalence studies.

Cost-effectiveness argument: Home units cost $2,000–$4,000 and last 5+ years. This is less expensive than 2–3 years of in-office sessions, which cost $50–$200 per session for the insurer.

Dermatologist supervision plan: Specify that treatment will be initiated and supervised by your dermatologist, with dose protocols, safety monitoring, and regular in-person check-ins to address side effects.

Safety monitoring: Document that UV exposure logging will be maintained and that your dermatologist will review treatment records.

UVA and PUVA: When Indicated

While NB-UVB is the most commonly used phototherapy for plaque psoriasis, PUVA (psoralen + UVA) may be used for specific indications — palmoplantar psoriasis, refractory cases, and as a second-line option. If PUVA is denied:

• Document failure on NB-UVB with specific session count and response data
• Note clinical rationale for PUVA (e.g., palmoplantar location not adequately treated by full-body NB-UVB)
• Cite AAD guidelines supporting PUVA for appropriate psoriasis subtypes

Using Phototherapy Appeals to Meet Biologic Step Therapy Requirements

If your insurer requires phototherapy as a step before biologic approval, request written confirmation of exactly what constitutes a "failed" phototherapy trial. Common insurer-specific requirements:

• Minimum number of sessions (typically 20–30)
• Duration of trial (typically 3–4 months)
• Documentation of severity scores before and after
• Reason for failure: inadequate response, intolerable side effects, or access barriers

If you cannot access phototherapy and this prevents you from meeting the step therapy requirement for a biologic, document the access barrier in detail and request a step therapy exception based on inability to access the required step.

NPF and AAD Phototherapy Resources

The National Psoriasis Foundation (NPF) and AAD publish phototherapy guidelines that explicitly support both in-office and home NB-UVB as equivalent, evidence-based treatment options. The NPF also has a dedicated insurance access program and model appeal letters for phototherapy denials.

Fight Back With ClaimBack

ClaimBack can generate a complete phototherapy appeal — addressing session limits, home unit denials, and step therapy circular loops — using NPF and AAD guideline citations.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal